Akoya biosciences and neracare enter into an exclusive agreement to enable personalized therapy selection for early-stage melanoma patients

Leveraging akoya's market-leading phenoimager ht platform and clinical development expertise with neracare's immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients. leveraging akoya's market-leading phenoimager ht platform and clinical development expertise with neracare's immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients.
AKYA Ratings Summary
AKYA Quant Ranking